Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Oncolytics Biotech Inc (ONCY)

Oncolytics Biotech Inc (ONCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 106,146
  • Shares Outstanding, K 106,146
  • Annual Sales, $ 0 K
  • Annual Income, $ -23,140 K
  • EBIT $ -25 M
  • EBITDA $ -25 M
  • 60-Month Beta 0.97
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.06
  • Number of Estimates 1
  • High Estimate -0.06
  • Low Estimate -0.06
  • Prior Year -0.07
  • Growth Rate Est. (year over year) +14.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8622 +13.11%
on 12/31/25
1.0600 -8.00%
on 12/17/25
-0.0179 (-1.80%)
since 12/12/25
3-Month
0.8614 +13.21%
on 11/28/25
1.3200 -26.12%
on 10/28/25
-0.2348 (-19.40%)
since 10/14/25
52-Week
0.3258 +199.32%
on 06/06/25
1.5100 -35.42%
on 09/29/25
+0.1652 (+20.40%)
since 01/14/25

Most Recent Stories

More News
The $69B Precision Pivot: Why Biomarker Platforms are Igniting a New Oncology Gold Rush

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The genomics in cancer care market is on a massive tear, projected to hit $69.16 billion by 2032 as doctors...

ONCY : 0.9755 (-2.45%)
BCT.TO : 6.98 (-54.14%)
ACRV : 1.6900 (-0.59%)
LLY : 1,067.50 (-0.90%)
BCTX : 4.95 (-54.67%)
GLSI : 30.69 (+5.75%)
CATX : 2.63 (+4.78%)
Oncolytics Biotech® Appoints John McAdory as EVP of Strategy and Operations and Yujun Wu to Lead Biostatistics

SAN DIEGO, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced...

ONCY : 0.9755 (-2.45%)
CGON : 53.64 (+2.02%)
TAK : 16.39 (+2.37%)
Stocks in play: Oncolytics Biotech Inc

Announced updated clinical data from GOBLET Cohort 4 in patients with third-line metastatic squamous ...

ONCY : 0.9755 (-2.45%)
Oncolytics Biotech® Announces Updated Clinical Data from GOBLET Cohort 4 Demonstrating Activity of Pelareorep Plus Atezolizumab in Third-Line Anal Cancer

Compared to the historical benchmark, pelareorep-atezolizumab nearly tripled ORR  Combination achieved encouraging median DOR of almost 17 months Data establishes clear path in indication with...

ONCY : 0.9755 (-2.45%)
Stocks in play: Oncolytics Biotech Inc.

Announced proposal to change the Company’s jurisdiction of incorporation from Alberta, Canada, to the ...

ONCY : 0.9755 (-2.45%)
Oncolytics Biotech® Outlines Strategic Rationale for Proposal to Change Jurisdiction of Incorporation to Nevada

SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech ® Inc. (Nasdaq: ONCY) (“ Oncolytics ” or the “ Company ”), a clinical-stage immunotherapy company developing pelareorep, today...

ONCY : 0.9755 (-2.45%)
The $537B Precision Pivot: Why Molecular Monitoring is the New Oncology Standard

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – The war on cancer is moving into a high-tech era of molecular-guided defense. The genomics in cancer care...

ONCY : 0.9755 (-2.45%)
PYXS : 1.9400 (+3.19%)
PSNL : 8.97 (+2.16%)
NBP : 3.53 (-3.29%)
TOI : 3.37 (-4.53%)
Stocks in play: Oncolytics Biotech Inc

Announced the expansion of its gastrointestinal Tumor Scientific Advisory Board with the appointment ...

ONCY : 0.9755 (-2.45%)
Targeted Precision: Rare Disease Assets Attract Record Regulatory Momentum

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – Baystreet.ca News Commentary – Genomics-driven cancer diagnostics are accelerating market growth, with the genomics in cancer care market...

ONCY : 0.9755 (-2.45%)
IDYA : 36.03 (+2.68%)
ZLAB : 19.74 (+5.45%)
CHRS : 1.6700 (-1.76%)
HALO : 72.09 (+0.59%)
Oncolytics Biotech® Expands Its Gastrointestinal Tumor Scientific Advisory Board with the Addition of Dr. Eileen O’Reilly, Dr. Neil Segal, and Dr. Van Morris

New members bring deep experience in pancreatic, colorectal, and anal cancers to guide pelareorep’s development as a platform immunotherapy across GI tumors Company...

ONCY : 0.9755 (-2.45%)

Business Summary

Oncolytics Biotech, Inc. focuses on the discovery and development of pharmaceutical products for the treatment of a wide variety of human and companion pet cancers. The Company was formed to explore the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated...

See More

Key Turning Points

3rd Resistance Point 1.0900
2nd Resistance Point 1.0600
1st Resistance Point 1.0300
Last Price 0.9755
1st Support Level 0.9700
2nd Support Level 0.9400
3rd Support Level 0.9100

See More

52-Week High 1.5100
Fibonacci 61.8% 1.0576
Last Price 0.9755
Fibonacci 50% 0.9179
Fibonacci 38.2% 0.7782
52-Week Low 0.3258

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar